Heart failure in South America

Current Cardiology Reviews

Volumn 9, Issue 2, 2013, Pages 147-156

  Bocchi, Edimar Alcides ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiomyopathy; Chagas' disease; Endomyocardial fibrosis; Epidemiology; Heart failure; Hypertrophic cardiomyopathy; Prognosis; Restrictive cardiomyopathy; Rheumatic fever; Treatment; Valve disease

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; SPIRONOLACTONE;

ARTICLE; BRAZIL; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; ISCHEMIC CARDIOMYOPATHY; MULTICENTER STUDY (TOPIC); OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; RHEUMATIC FEVER; VALVULAR HEART DISEASE; CAUSE OF DEATH; COMORBIDITY; EPIDEMIOLOGY; HOSPITALIZATION; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; REVIEW; SOUTH AMERICA; STATISTICS; SURVIVAL RATE; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; HEART VALVE DISEASES; STATISTICS AND NUMERICAL DATA; TRENDS;

BRAZIL; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CAUSALITY; CAUSE OF DEATH; CHAGAS DISEASE; COMORBIDITY; HEART FAILURE; HEART VALVE DISEASES; HOSPITALIZATION; HUMANS; PROGNOSIS; RHEUMATIC FEVER; SOUTH AMERICA; SURVIVAL RATE;

EID: 84894490737     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X11309020007     Document Type: Article

References (93)

1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case- fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
2. Levi F, Lucchini F, Negri E et al. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002;88:119-24.
3. Jemal A, Ward E, Hao Y et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255-9.
4. Yach D, Hawkes C, Gould CL et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004;291:2616-22
5. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J 2010; 31:784-793.
6. Gheorghiade M, Braunwald E. Hospitalizations for heart failure in the United States-a sign of hope. JAMA 2011;306:1705-6. Erratum in: JAMA 2012; 307:563.
7. Chen J, Normand S-LT, Wang Y et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011; 306:1669-1678
8. http://w3.datasus.gov.br/datasus/datasus.
9. http://www.seade.gov.br.
10. Bocchi EA, Guimarães G, Tarasoutshi F et al. Cardiomyopathy, adult valve disease and heart failure in South America. Heart 2009; 95:181-9.
11. Schocken DD, Benjamin EJ, Fonaroww GG, et al. Prevention of heart failure. A Scienfic Statement from the American Heart Association Councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation 2008;13;117:2544-65.
12. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries;a review of the literature. Int J Cardiol 2001; 80:213-219.
13. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004; 88:1145-72.
14. Miller LW, Missov ED. Epidemiology of heart failure. Cardiology Clinics 2001;19:547-555.
15. Giorgi MA, Guerrero RAA, Arins MGVB et al. Hospital costs analysis of heart failure with preserved versus depressed systolic function. Rev Argent Cardiol 2008; 76:20-6.
16. Gaui EN, Klein CH, Oliveira GM. Mortality due to heart failure: extended analysis and temporal trend in three states of Brazil. Arq Bras Cardiol. 2010;94:55-61.
17. Godoy HL, Silveira JA, Segalla E et al. Hospitalization and mortality rates for heart failure in public hospitals in São Paulo. Arq Bras Cardiol 2011; 97:402-7.
18. Pereira Barreto AC, Cuce MR et al. Insuficiência cardíaca em grande hospital terciário de São Paulo. Arq Bras Cardiol 1998; 71:15-20.
19. McSwain M, Martin TC, Amaraswamy R. The prevalence, etiology, and treatment of congestive heart failure in Antigua and Barbuda. West Indian Med J 1999; 67: 53-62.
20. Perna ER, Barbagelata A, Grinfeld L et al. Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade. Am Heart J 2006; 151: 84-91.
21. Tavares LR, Victer H, Linhares M et al. Epidemiology of decompensated heart failure in the city of Niterói - EPICA - Niterói Project. Arq Bras Cardiol 2004; 82: 125-128.
22. Mangini S, Silveira FS, Silva CP et al. Decompensated heart failure in the emergency department. Arq Bras Cardiol. In press.
23. Bocchi EA, Vilas-Boas F, Moreira MC et al. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF Study. Arq Bras Cardiol 2008; 90: 201-210.
24. Bocchi EA, Guimarães G, Moura L et al. Markers of levosimendan efficacy in the treatment of congestive heart failure - The BELIEF Study: a prospective multicenter study. Eur J Heart Fail 2003; 2: 1-206.
25. Rohde LE, Clausell N, Ribeiro JP, et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int J Cardiol 2005;102:71-7.
26. Barreto ACP, Del Carlo CH, Cardoso J, et al. Hospital readmissions and death from heart failure: rates still alarmning. Arq Bras Cardiol 2008; 91:309-314.
27. Jorge JEL, Cagy M, Mesquita ET et al. Seasonal variation i hospitalizations due to heart failure in Niteroi city, Southeastern Brazil. Rev Saude Publica 2009; 43:555-7.
28. Goldraich L, Clausell N, Biolo A et al. Clinical predictors of preserved left ventricular ejection fraction in decompensated heart failure. Arq Bras Cardiol 2010; 94:364-71, 385-93.
29. Silva TJ, Jerussalmy CS, Farfel JM et al. Predictors of in-hospital mortality among older patients. Clinics 2009; 64:613-8.
30. Freitas HFG, Chizzola PR, Paes AT et al. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol 2005; 102: 239-247.
31. Bocchi EA. Update on indications and results of the surgical treatment of heart failure. Arq Bras Cardiol 1994; 63:523-30.
32. Doval HC, Nul DR, Grancelli HO et al. Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-498.
33. Mendez GF, Betancourt L, Galicia-Mora G. The impact of heart failure clinic in the improvement on quality of life of heart failure patients in México. Int J Cardiol 2007; 115: 242-243.
34. Bocchi EA, Cruz F, Guimarães G; et al. A Long-term Prospective Randomized Control Study Using Repetitive Education at Six-Month Intervals and Monitoring for Heart Failure - The REMADHE Study. Circulation: Heart Failure 2008; 1:115-24.
35. Silva CP, Bacal F, Pires PV, et al. Heart failure profile at the beta blockers era. Arq Bras Cardiol 2007; 88:419-22.
36. Domingues FB, Clausell N, Aliti GB et al. Education and telephone monitoring by nurses of patients with heart failure: randomized clinical trial. Arq Bras Cardiol 2011; 96:233-9.
37. Moutinho MAE, Colucci FA, Alcoforado V et al. Heart failure with preserved ejection fraction and systolic dysfunction in the community. Arq Bras Cardiol 2008; 90: 132-137.
38. Balieiro HM, Osugue RK, Rangel SP, et al. Clinical and demographic profile and quality indicators for heart failure in a rural area. Arq Bras Cardiol 2009; 93:637-42, 687-91.
39. Torre-Amione G, Anker SD, Bourge RC, et al. for the advanced chronic heart failure clinical assessment of immune modulation therapy investigators. Results of a non-specific immunomodulation therapy in chronic heart failure. Lancet 2008; 371:228-236.
40. Ather S, Chan W, Bozkurt B et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59:998-1005.
41. Santos EB, Tello BS, Villacorta H, et al. Anemia and heart failure in a community-based cohort: comparison with a specialized outpatient clinic. Arq Bras Cardiol 2010; 94:102-8.
42. Souza WN, Araújo CM, Silva SA et al. Anemia, renal dysfunction and malnutrition associated with heart failure in patients with valvulopathy. Arq Bras Cardiol 2010; 94:794-8.
43. Villacorta H, Saenz-Tello BF, Santos EB, et al. Renal dysfunction and anemia in patients with heart failure with reduced versus normal ejection fraction. Arq Bras Cardiol 2010; 94:357-63, 378-84.
44. GESICA Investigators. Randomized trial of telephone intervention in chronic heart failure: DIAL trial. BMJ 2005; 331:425
45. Silva CHM. and Committee - São Paulo Pediatric Rheumatology Society Rev Hosp Clin Fac Med S Paulo 1999; 54:85-90.
46. Meira ZM, Goulart EM, Colosimo EA et al. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. Heart 2005; 91:1019-22
47. Carapetis JR. Rheumatic Heart Disease in developing countries. N Engl J Med 2007 357:439.
48. Nordet P. Fiebre Reumática en Cuba: incidencia, prevalencia, mortalidad y caracteristicas clínicas. Revista Cubana de Cardiologia y Cirurgia Cardiovascular 1991; 5: 25-33
49. Prokkopowitsh AS, Lotufo PA.Epidemiologia da febre reumática no século XXI. REVSOCESP 2005; 15:1-6.
50. Borges F, Barbosa ML, Borges RB et al. Clinical and demographic characterisitics of 99 rheumatic episodes of rheumatic fever in Acre, the Brazilian Amazon. Arq Bras Cardiol 2005; 84:111-4.
51. Barreto ACP, Mady C, Oliveira AS, et al. Clinical meaning of ascites in patients with endomyocardial fibrosis. Arq Bras Cardiol 2002; 78:196-9.
52. Silva CP, Bacal F, Benvenuti LA, Bocchi EA. Desmin-related restrictive cardiomyopathy. Arq Bras Cardiol 2007; 89:150-152.
53. Kushwara S, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267-76.
54. Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis:still a mystery after 60 years. PloS Negl Trop Dis 2008; 2:e-97.
55. Barretto AC, da Luz PL, de Oliveira SA et al. Determinants of survival in endomyocardial fibrosis. Circulation 1989; 80:I177-82.
56. Barretto AC, Mady C, Nussbacher A et al. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998; 67:19-25.
57. Puigbo JJ, Combellas I, Acquatella H et al. Endomyocardial disease in South America - report on 23 cases in Venezuela. Postgrad Med J 1983;59:162-9.
58. Barreto ACP, Mady C, Pileggi F. Endomyocardial fibrosis. Longitudinal follow-up of patients not treated with surgery. Arq Bras Cardiol 1996; 67:285-8.
59. de Oliveira SA, Pereira Barreto AC, Mady C, et al. Surgical treatment of endomyocardial fibrosis: a new approach. J Am Coll Cardiol 1990; 16:1246-51
60. De Freitas HF, de Castro PP, Chizzola PR, et al. Heart transplantation in a patient with endomyocardial fibrosis. Arq Bras Cardiol 2005; 84:49-50.
61. Andrade JP, Marin-Neto JA, Paola AA et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Arq Bras Cardiol 2011; 97(2 Suppl 3):1-48.
62. Bocchi EA. Exercise training in Chagas' cardiomyopathy: trials are welcome for this neglected heart disease. Eur J Heart Fail 2010; 12:782-4.
63. Melo LM, Souza GE, Valim LR, et al. Study of pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq Bras Cardiol 2010; 95:655-62.
64. Aras R, da Matta JA, Mota G, Gomes I, Melo A. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq Bras Cardiol 2003; 81: 414-6, 411-3.
65. Bocchi EA, Cruz F, Guimarães G, Pinho Moreira LF, et al. Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circ Heart Fail 2008; 1:115-124.
66. Nogueira PR, Rassi S, Corrêa Kde S. Epidemiological, clinical e therapeutic profile of heart failure in a tertiary hospital. Arq Bras Cardiol 2010;95:392-8.
67. Santo AH. Tendência da mortalidade relacionada a doença de Chagas, Estado de São Paulo, Brazil 1985 a 2006: estudo usando causas múltiplas de morte. Am J Public Health 2009;26:299:309.
68. Pearlman JD. Chagaśdisease in northern California, No longer an endemic diagnosis. Am J Med 1983;75:1057-60.
69. Bellotti G, Bocchi EA, de Moraes AV, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J 1996;131:301-7. Erratum in: Am Heart J. 1998;135:550.
70. Mocelin AO, Issa VS, Bacal F, Guimarães GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005;7:869-73.
71. Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 1996;61:1727-1733.
72. Bocchi EA, Kalil R, Bacal F. et al. Magnetic Resonance Imaging in Chronic Chagas' Disease: Correlation with Endomyocardial Biopsy Findings and Gallium-67 Cardiac Uptake. Echocardiography. 1998;15:279-288.
73. Higuchi Mde L, Kawakami J, Ikegami R, et al. Do Archaea and bacteria co-infection have a role in the pathogenesis of chronic chagasic cardiopathy? Mem Inst Oswaldo Cruz 2009;104(Suppl 1):199-207.
74. Bocchi EA Update on indications and results of the surgical treatment of heart failure. Arq Bras Cardiol 1994; 63:523-30.
75. Issa VS, Amaral AF, Cruz FD, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010; 3:82-8.
76. Bocchi EA, Marcondes-Braga FG, Bacal F, et al. 2012 Update on Brazilian Guidelines of Chronic Heart Failure. Arq Bras Cardiol 2012; 98(1 Suppl 1):1-33.
77. Issa VS, Guimarães GV, Rezende MV, et al. Effects of bisoprolol on cardiac function and exercise in patients with heart failure. Arq Bras Cardiol 2007;88:340-5.
78. Issa VS, Bocchi EA. Antitrypanosomal agents: treatment or threat? Lancet 2010; 376:768.
79. Campos SV, Strabelli TM, Amato Neto V et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant 2008; 27:597-602.
80. Bocchi EA, Bellotti G, Uip D, et al. Long-term follow-up after heart transplantation in Chagas' disease. Transplant Pro 1993; 25(1 Pt 2):1329-30.
81. Bocchi EA, Bacal F, Guimarães G, et al. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int J Cardiol 2010; 138:94-7.
82. Bocchi EA, Bellotti G, Vilella de Moraes A, et al. Clinical outcome after left ventricular surgical remodeling in patients with idiopathic dilated cardiomyopathy referred for heart transplantation: short-term results. Circulation 1997; 96(9 Suppl):II-165-71; discussion II-171-2.
83. Bocchi EA, Vieira ML, Fiorelli A, et al. Hemodynamic and neurohormonal profile during assisted circulation with heterotopic artificial ventricle followed by heart transplantation. Arq Bras Cardiol 1994; 62:23-7.
84. Galantier J, Moreira LF, Benício A, et al. Hemodynamic performance and inflammatory response during the use of VAD-InCor as a bridge to transplant. Arq Bras Cardiol 2008; 91(5):327-34.
85. Cubillos-Garzon, Casas JP, Morillo CA, et al. Congestive heart failure in Latin America: the next epidemic. Am Heart J 2004;147:412-7.
86. Arnett DK, McGovern PG, Jacobs DR Jr et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol 2002; 156:929-35.
87. Gwatkin DR, Guillot M, Heuveline P. The burden of disease among the global poor. Lancet 1999; 354:586-9.
88. United Nations Development programme (UNDP). Millennium developement goals 2005. at http://www.undp.org/mdg/abcs.html.
89. Tibazarwa KB, Volmink JA, Mayosi BM. The incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart 2008; 94:1534-40.
90. Mota C. Rheumatic fver in the 21st century. Cardiol Young 2003; 13:491-4.
91. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. World Health Organ Tech Rep Ser 2004; 923;1-122.
92. Nordet P, Lopez R, Dueñas A et al. Prevention and control of rheumatic fever and rheumatic heart disease; the Cuban experience.(1986-1966-2002). Cardiovasc J Afr 2008; 19:135-40.
93. Marin-Neto JA, Rassi A Jr, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156:37-43.